openPR Logo
Press release

Metastatic Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight

03-23-2023 01:12 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Metastatic Breast Cancer Pipeline

Metastatic Breast Cancer Pipeline

Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight

DelveInsight's 'Metastatic Breast Cancer Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Breast Cancer pipeline domain.

To know more about Metastatic Breast Cancer Pipeline, click here @ https://www.delveinsight.com/report-store/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Metastatic Breast Cancer Pipeline Report
• DelveInsight's Metastatic Breast Cancer Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Metastatic Breast Cancer treatment.
• Key Metastatic Breast Cancer pipeline therapies in various stages of development include Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others.
• The leading Metastatic Breast Cancer companies with various Metastatic Breast Cancer medications include RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others are developing novel drug candidates to improve the Metastatic Breast Cancer treatment landscape.
• On May 04, 2022, Rhizen Pharmaceuticals AG announced the presentation of promising interim data from an ongoing Ph2 trial of Tenalisib in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany from May 3-5, 2022. Tenalisib was well tolerated and showed encouraging preliminary efficacy as a single agent in both primary and secondary resistant mBC; Data supports further development of Tenalisib in patients with HR+ and HER2- MBC.
• In April 2022, Alphamab Oncology announced that data from the phase II clinical study of the chemo-free regimen of KN026 in combination with KN046 (KN026-203) were presented as an E-poster at the AACR Annual Meeting 2022 (AACR 2022). As of August 10, 2021, 24 patients with HER2-positive other solid tumors (non-breast cancer/gastric cancer) who received ≥1L prior systemic therapy were enrolled, 20 patients were evaluable for overall response: the ORR was 55.0%, the DCR was 85.0%, the 6-month PFS rate was 84.1%; Out of 11 evaluable CRC patients, the ORR and DCR was 45.5% and 90.9% respectively.
• In April 2022, Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL for the treatment of HER2-positive breast cancer in the neoadjuvant setting. Sponsored by Quantum Leap, the I-SPY 2.2 TRIAL is a continuation of the I-SPY 2 TRIAL that seeks to create personalized treatments by adapting therapies for each patient to optimize the clinical outcome.
• In March 2022, TYME Technologies, Inc. announced the availability of the poster abstract, "SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor-positive breast cancer," which was submitted by researchers from Georgetown University. The abstract was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA. In September 2021, TYME Technologies, Inc. announced that the first patient had been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative ("HR+/HER2-") breast cancer who previously received a CDK4/6 inhibitor regimen being conducted by Georgetown University (NCT04720664) at several MedStar Health hospitals. (MedStar Health is Georgetown's academic clinical partner.)

Request a sample and discover the recent breakthroughs and advances in treating Metastatic Breast Cancer @ https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Metastatic Breast Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Metastatic Breast Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Metastatic Breast Cancer pipeline landscape.

Metastatic Breast Cancer Overview
Metastatic Breast Cancer (also known as stage IV) is breast cancer that has progressed to another region of the body, most often the liver, brain, bones, or lungs. The five-year Metastatic Breast Cancer survival rate is 22%, with a three-year median Metastatic Breast Cancer life expectancy. The Metastatic Breast Cancer symptoms vary widely depending on where the disease has spread. The most frequent Metastatic Breast Cancer sign that have gone to the bone is a sudden, noticeable new pain. Tumor biopsy is one of the most important tests for Metastatic Breast Cancer diagnosis.
Systemic therapy, rather than surgery or radiation, is frequently used for Metastatic Breast Cancer treatment. Metastatic Breast Cancer treatment is intended to decrease tumors and limit their development, as well as relieve symptoms and enhance the quality of life. Metastatic Breast Cancer treatment may alter if one therapy stops functioning or the adverse effects become too bothersome.

Find out more about immunotherapy for Metastatic Breast Cancer@ Metastatic Breast Cancer Therapy - https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Metastatic Breast Cancer Therapeutics Assessment
The Metastatic Breast Cancer Pipeline report proffers an integral view of the Metastatic Breast Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Metastatic Breast Cancer Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
• Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Key Metastatic Breast Cancer Companies: RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.
• Key Metastatic Breast Cancer Pipeline Therapies: Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001,GNC-035, RGT-419B, Hemay022, SCR-6852, and others.

Dive deep into rich insights into new Metastatic Breast Cancer drugs, visit @ Metastatic Breast Cancer Treatment- https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Breast Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Breast Cancer Pipeline Therapeutics
6. Metastatic Breast Cancer Pipeline: Late Stage Products (Phase III)
6.1 Disitamab Vedotin: RemeGen
6.2 trastuzumab duocarmazine: Byondis B.V.
7. Metastatic Breast Cancer Pipeline: Mid Stage Products (Phase II)
7.1 MRG002: Shanghai Miracogen Inc.
8. Metastatic Breast Cancer Pipeline: Early Stage Products (Phase I)
8.1 DAN-222: Dantari, Inc.
9. Metastatic Breast Cancer Pipeline: Preclinical Stage Products
10. Metastatic Breast Cancer Pipeline Therapeutics Assessment
11. Inactive Products in the Metastatic Breast Cancer Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies in the Metastatic Breast Cancer Pipeline
14. Key Products in the Metastatic Breast Cancer Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Metastatic Breast Cancer pipeline therapeutics, reach out @ https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight here

News-ID: 2986912 • Views:

More Releases from DelveInsight Business Research

Bartonellosis Market Analysis 2032: Epidemiology, Market Size, Share, Treatment Options, Clinical Trials, Leading Companies & Growth Trends by DelveInsight
Bartonellosis Market Analysis 2032: Epidemiology, Market Size, Share, Treatment …
(New York, USA) DelveInsight's "Bartonellosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Bartonellosis, historical and forecasted epidemiology as well as the Bartonellosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Bartonellosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bartonellosis market size from 2019 to
Atypical Hemolytic Uremic Syndrome Market Forecasted to Expand by 2032, Projected by DelveInsight | Key Players Include Omeros Corporation, Akari Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Hoffmann-La Roche, and Chugai Pharmaceutical
Atypical Hemolytic Uremic Syndrome Market Forecasted to Expand by 2032, Projecte …
(Albany, USA) DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Atypical Hemolytic Uremic Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies,
Hyperhidrosis Market Forecast 2032: Epidemiological Insights, Market Dynamics, Therapeutic Innovations, Clinical Trial Landscape by DelveInsight | Leading Companies - Botanix Pharmaceuticals, GSK Plc, Allergan, Brickell Biotech, Atacama
Hyperhidrosis Market Forecast 2032: Epidemiological Insights, Market Dynamics, T …
(New York, USA) DelveInsight's "Hyperhidrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hyperhidrosis, historical and forecasted epidemiology as well as the Hyperhidrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report on the Hyperhidrosis market presents up-to-date treatment practices, emerging drugs, the market share of different therapies, and the present and projected size of the Hyperhidrosis market
Projected Expansion in Chronic Lymphocytic Leukemia Market Forecasted by 2032, DelveInsight Predicts | Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novar
Projected Expansion in Chronic Lymphocytic Leukemia Market Forecasted by 2032, D …
(New York, USA) DelveInsight's "Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Chronic Lymphocytic Leukemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boost
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top